Should You Buy iTeos Therapeutics Inc (ITOS) Stock on Friday?

iTeos Therapeutics Inc (ITOS) stock is lower by 13.14% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

iTeos Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ITOS!

See Full ITOS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ITOS Stock Today?

iTeos Therapeutics Inc (ITOS) stock has risen 3.35% while the S&P 500 is lower by -0.81% as of 1:30 PM on Friday, Oct 13. ITOS is higher by $0.29 from the previous closing price of $8.57 on volume of 514,518 shares. Over the past year the S&P 500 is higher by 20.62% while ITOS is lower by -51.13%. ITOS lost -$0.82 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for iTeos Therapeutics Inc click here.

More About iTeos Therapeutics Inc

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Click Here to get the full Stock Report for iTeos Therapeutics Inc stock.